08_CD Development_NNP Ensuring_NNP that_IN our_PRP$ growing_VBG range_NN of_IN candidate_NN drugs_NNS are_VBP developed_VBN effectively_RB to_TO meet_VB the_DT future_JJ needs_NNS of_IN patients_NNS is_VBZ a_DT high_JJ priority_NN ._.
John_NNP Patterson_NNP ,_, Executive_NNP Director_NNP ,_, Development_NNP People_NNS in_IN our_PRP$ Development_NNP organization_NN focus_NN on_IN developing_VBG better_JJR drugs_NNS faster_RBR ._.
They_PRP work_VBP globally_RB in_IN therapy_NN area-led_JJ product_NN teams_NNS that_WDT bring_VBP together_RB all_PDT the_DT relevant_JJ functional_JJ skills_NNS and_CC experience_NN needed_VBN for_IN the_DT robust_JJ ,_, rapid_JJ progress_NN of_IN new_JJ medicines_NNS and_CC the_DT management_NN of_IN development_NN risks_NNS ._.
We_PRP aim_VBP to_TO continuously_RB improve_VB the_DT efficiency_NN of_IN our_PRP$ R&D_NN by_IN simplifying_VBG our_PRP$ processes_NNS ,_, speeding_VBG up_RP decision_NN making_VBG and_CC investing_VBG in_IN areas_NNS directly_RB linked_VBN to_TO increasing_VBG the_DT quality_NN and_CC number_NN of_IN new_JJ products_NNS ._.
A_DT new_JJ clinical_JJ organisational_JJ structure_NN was_VBD announced_VBN in_IN October_NNP 2004_CD to_TO support_VB these_DT practices_NNS and_CC further_JJ enhance_VB productivity_NN ._.
In_IN January_NNP 2005_CD ,_, we_PRP appointed_VBD an_DT Executive_NNP Director_NNP for_IN Development_NNP a_DT new_JJ Board_NNP position_NN as_IN part_NN of_IN our_PRP$ accelerated_VBN significant_JJ program_NN of_IN change_NN to_TO review_VB our_PRP$ pipeline_NN and_CC optimise_VB the_DT contribution_NN of_IN our_PRP$ development_NN and_CC regulatory_JJ functions_NNS ._.
In_IN 2004_CD ,_, 18_CD candidate_NN drugs_NNS were_VBD selected_VBN 15_CD in_IN 2003_CD and_CC 11_CD in_IN 2002_CD ._.
By_IN the_DT end_NN of_IN the_DT year_NN ,_, there_EX were_VBD 31_CD projects_NNS in_IN the_DT preclinical_JJ phase_NN and_CC 17_CD projects_NNS in_IN clinical_JJ phase_NN 1_CD ,_, 17_CD projects_NNS in_IN clinical_JJ phase_NN 2_CD and_CC 25_CD projects_NNS in_IN clinical_JJ phase_NN 3_CD ._.
During_IN the_DT year_NN we_PRP also_RB concentrated_VBD on_IN progressing_VBG regulatory_JJ filings_NNS for_IN Exanta_NNP and_CC supporting_VBG continued_VBN launches_NNS of_IN new_JJ products_NNS ._.
We_PRP also_RB continue_VBP to_TO look_VB at_IN all_PDT the_DT ways_NNS our_PRP$ existing_VBG products_NNS can_MD be_VB used_VBN or_CC improved_VBN to_TO get_VB the_DT most_RBS benefit_VB for_IN patients_NNS and_CC in_IN 2004_CD made_VBD regulatory_JJ submissions_NNS for_IN new_JJ uses_NNS for_IN Nexium_NNP ,_, Symbicort_NNP and_CC Atacand_NNP ._.
With_IN effect_NN from_IN 1_CD January_NNP 2005_CD thinking_VBG ahead_RB
